The AIDS syndrome often manifests itself clinically as Pneumocystis carinii pneumonia. At the time of presentation, patients are short of breath, with evidence of gas exchange and radiologic abnormalities. Treatment usually involves hospitalization and parenteral therapy. While the infection is confined to the lung, therapy is often unsuccessful because of systemic toxicity and, we suspect, inadequate drug delivery to the lung. The goal of this proposal, in conjunction with Pulmonary Function section of this Clinical Studies Group project, is to detect patients with P. carinii infection at the earliest possible time and establish the optimal mode of therapy. This project has the following specific aims: (1) To quantitate the delivery of aerosolized pentamidine to patients with AIDS-related Pneumocystis pneumonia. (2) To determine the effectiveness of aerosolized pentamidine in hospitalized and ambulatory patients. (3) To relate the clinical response of intravenous and aerosolized pentamidine to dose, pulmonary fluid, and blood levels. (4) To study the effects of intravenous and aerosolized pentamidine on islet cell function. Using radiolabeled aerosols and nuclear medicine techniques, we will optimize the aerosolized delivery of pentamidine in patients with P. carinii pneumonia. In addition to the usual hospitalized patients presenting with clinical signs and symptoms, we will attempt to define, using pulmonary function testing (PFTs), a clinically asymptomatic patient population with early infection. With an optimized aerosol system and HPLC determined blood, pulmonary lavage fluid, and pulmonary macrophage levels of pentamidine, the effectiveness of aerosolized and intravenous therapy will be compared in ambulatory and hospitalized patients. All patients will be followed clinically and with serial PFTs and broncho-alveolar lavage. These data, combined with measurement of pancreatic hormone function during therapy could lead to an improved clinical response, reduced drug toxicity, and shortened hospitalization.

Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
State University New York Stony Brook
Department
Type
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Morrison, S A; Pearson, S L; Steigbigel, R T (1998) Anti-F(ab')2 antibody in HIV type 1 infection: relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120. AIDS Res Hum Retroviruses 14:491-8
Schubach, W H; Horvath, G; LeVea, C et al. (1997) Chromatin structure of the lymphocyte Fc epsilon receptor gene (CD23): identification of an upstream transcriptional enhancer. J Immunol 158:2228-35
Moorjani, H; Craddock, B P; Morrison, S A et al. (1996) Impairment of phagosome-lysosome fusion in HIV-1-infected macrophages. J Acquir Immune Defic Syndr Hum Retrovirol 13:18-22
Cohen, A J; Steigbigel, R T (1996) Eosinophilia in patients infected with human immunodeficiency virus. J Infect Dis 174:615-8
Handley, M A; Steigbigel, R T; Morrison, S A (1996) A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. J Virol 70:4451-6
O'Riordan, T G; Smaldone, G C (1994) Regional deposition and regional ventilation during inhalation of pentamidine. Chest 105:396-401
O'Riordan, T G; Palmer, L B; Smaldone, G C (1994) Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery. Am J Respir Crit Care Med 149:214-9
O'Riordan, T G; Baughman, R P; Dohn, M N et al. (1994) Lobar pentamidine levels and Pneumocystis carinii pneumonia following aerosolized pentamidine. Chest 105:53-6
Nuovo, G J; Becker, J; Burk, M W et al. (1994) In situ detection of PCR-amplified HIV-1 nucleic acids in lymph nodes and peripheral blood in patients with asymptomatic HIV-1 infection and advanced-stage AIDS. J Acquir Immune Defic Syndr 7:916-23
Suzuki, K; Craddock, B P; Okamoto, N et al. (1993) Detection of human immunodeficiency virus (HIV) by colorimetric assay for reverse transcriptase activity on magnetic beads. Biotechnol Appl Biochem 18 ( Pt 1):37-44

Showing the most recent 10 out of 27 publications